Table 1.

Clinical Characteristics of the Patients Enrolled in the 2 Groups

Control Group (n=146)RenalGuard Group (n=146)
Age, y75±976±8
Male, n (%)103 (70.5)88 (60.5)
Weight, kg 78±15 77±14
Height, m1.65±0.71.65±0.7
Body mass index, kg/m229±528±5
Blood pressure, mm Hg
    Systolic152±27152±27
    Diastolic 78±10 77±13
    Mean103±13102±15
LV ejection fraction, %48±1046±11
LV end-diastolic pressure, mm Hg14±714±7
LV dysfunction and/or unstable hemodynamic conditions, n (%)41 (28)42 (29)
    LV ejection fraction, %36±836±10
    LV ejection fraction ≤30%, n (%)20 (13.5)22 (15)
Systemic hypertension, n (%)144 (98)143 (98)
Diabetes mellitus, n (%)104 (71)101 (69)
Peripheral chronic artery disease, n (%)27 (18.5)28 (19)
Drugs, n (%)
    ACE inhibitor67 (46)70 (48)
    Calcium channel blocker44 (30)36 (25)
    Angiotensin II receptor inhibitor45 (31)42 (29)
    Diuretics85 (58)93 (64)
    β-blockers88 (60)92 (63)
    Statins111 (76)108 (74)
Procedure performed, n (%)
    Coronary angiography60 (41)51 (35)
    PCI58 (40)71 (49)
    Coronary angiography and ad hoc PCI17 (12)11 (7.5)
    Peripheral procedure11 (6)13 (9)
Volume of contrast media, mL145±79135±76
    Contrast ratio >1, n (%)35 (24%)28 (19)
  • LV indicates left ventricular; ACE, angiotensin-converting enzyme; and PCI, percutaneous coronary intervention.